rare disease drugs

South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerat...

The Chinese government has warned South Korean companies of retributions for exporting any product containing its critical metals to US military con...

South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply contracts for its flags...

Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...

South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to autoimmune disease t...

South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug combination in clinical tria...

Samsung Group companies will jointly invest $10 million in C2N Diagnostics LLC, a U.S.-based company specializing in blood-based Alzheimer’s d...

Chong Kun Dang Pharmaceutical Corp. is discussing building a research center and a plant in Siheung, about 30 kilometers southwest of Seoul, with th...

Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...

SAN FRANCISCO -- Lotte Biologics Co., the drug consignment development and production unit of South Korean conglomerate Lotte Group, will seek to wi...

SAN FRANCISCO – South Korea’s leading biosimilar drug developer Celltrion Inc. seeks to acquire a domestic health food maker as early as...

South Korea’s SK Biopharmaceuticals Co. has signed a deal with Brazil’s Eurofarma Laboratórios S.A. to establish a joint venture ...

SK Ecoplant Co., a South Korean construction engineering and waste management company under SK Group, partnered with German luxury carmaker BMW to...

Leclaza (ingredient: lazertinib), a new lung cancer treatment developed by South Korea’s Yuhan Corp. secured approval from the European Commis...

South Korea's Celltrion Inc. said on Wednesday it received new drug submission (NDS) approval from the Food and Drug Administration (FDA) for Steq...

South Korea's Boryung Corp. said on Thursday it signed a contract with Lotus Pharmaceutical, a Taiwanese oncology firm, for contract development and...

South Korea's SK Biopharmaceuticals Co. said on Tuesday it submitted the new drug application (NDA) for its flagship epilepsy drug Cenobamate to Chi...

Celltrion Inc.'s Remsima, the world’s first biosimilar monoclonal antibody, is on track to exceed 1 trillion won ($713 million) in sales this ...

South Korea’s Hanmi Pharmaceutical Co. announced on Thursday the launch of its anti-obesity drug candidate efpeglenatide has been rescheduled ...

Samsung Biologics Co., the world’s largest contract drugmaker, said on Wednesday it has signed two drug manufacturing contracts worth a combin...

South Korea's Celltrion Inc. said on Monday it released Steqeyma (ustekinumab) in Europe, the biosimilar of autoimmune disease treatment Stelara.T...

South Korean biosimilar maker Celltrion Inc. said on Monday its subcutaneous injection formulation for autoimmune diseases, Zymfentra (infliximab), ...

South Korea’s Celltrion Inc. said on Friday that its cancer treatments have captured a 90% market share in several Central American countries....

A new lung cancer treatment developed by South Korea’s Yuhan Corp. has secured approval from the US Food and Drug Administration (FDA) as a co...

South Korea's antibody-based biotech company IMBiologics announced on Friday that it signed a contract to transfer the technology of its autoimmune ...

South Korea's Celltrion Inc. announced on Tuesday that its autoimmune disease treatment Yuflyma (Low WAC, active ingredient adalimumab) is now avail...

South Korean biosimilar maker Celltrion Inc. said on Monday that its subcutaneous injection formulation for autoimmune diseases, Zymfentra (inflixim...

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Steqeyma, a biosimilar of the autoimmune dise...

South Korean biotech Huons Global Co. said on Tuesday that its research and development unit Huonslab has issued a domestic patent claiming a techno...

SEOUL—A North Korean diplomat posted in Cuba defected to South Korea with his family late last year, officials said this week, a rare esc...